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Abstract 
 
Anticoagulant therapy presents iatrogenic effects such as intracerebral hemorrhage (ICH). The 
latest anticoagulants on the market, direct oral anticoagulants (DOACs) such as apixaban, 
dabigatran and rivaroxaban, are reported to cause less ICH than other anticoagulants. Next to the 
ICH area, the thrombin is accumulated and the blood-brain barrier (BBB) is opened. The effects 
of thrombin on the BBB are largely mediated by the protease activated receptor (PAR) family, 
especially the PAR-1 isoform. Our hypothesis is that DOACs may limit the effects of thrombin 
on endothelial cells (of the BBB) alteration by a mechanism probably involving PAR-1 
activation. To test this hypothesis in vitro, we used HBEC-5i human brain endothelial cells as a 
human BBB model. The effects of thrombin under warfarin, heparin, rivaroxaban, apixaban, and 
dabigatran treatment on endothelial cells were then investigated by measuring of permeability 
and junction proteins: ZO-1 and VE-cadherin expressions and PAR-1 cleavage. 
Depending on the anticoagulant used, we observed three profiles of response of the endothelial 
cells after thrombin exposure: i) dabigatran treatment allowed maintaining the tightness of the 
endothelial monolayer; ii) other DOACs limited thrombin-induced alteration of the endothelial 
monolayer; and iii) pretreatment with warfarin and heparin did not protect from thrombin-
induced BBB breakdown. Pretreatment with DOACs clearly limited the impact of thrombin on 
PAR-1 cleavage in our model, contrary to other anticoagulants, associated with ZO-1 and VE-
cadherin expressions. In conclusion, DOACs seem to limit the alteration of the monolayer of 
endothelial cells of the BBB mediated by the thrombin/PAR-1 pathway. 
 
Keywords: Endothelial cells monolayer; Blood-brain barrier; Direct oral anticoagulants; 
Protease activated receptor-1; Thrombin; VE-cadherin; ZO-1 
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1. Introduction 
 In the last decade, direct oral anticoagulants (DOACs) have emerged as alternatives to 
other anticoagulants, such as vitamin K antagonists (VKAs) and low molecular weight heparin 
(LMWH), in the prevention of thromboembolic events. DOACs are reported to cause less 
intracerebral hemorrhage (ICH) effect than VKAs (Ezekowitz et al., 2007; Miller et al., 2012; 
Ruff et al., 2014). There are two types of DOACs: direct thrombin inhibitor (dabigatran)and 
factor Xa inhibitors (rivaroxaban and apixaban). 
ICH is a known iatrogenic effect occurring under anticoagulation therapy. In the 
literature, phase III clinical studies have shown a decrease in intracranial bleeding under 
DOACs compared to VKAs (warfarin) in patients suffering from atrial fibrillation (Connolly et 
al., 2009; Granger et al., 2011; Ogawa et al., 2011). It has also been reported in an in vivo 
murine model that rivaroxaban and dabigatran prevented hemorrhage in comparison to warfarin 
(Ploen et al., 2014; Sun et al., 2013). In ICH, thrombin, a known multifunctional serine protease 
and a fundamental component in the coagulation cascade to produce fibrin clots, has been 
largely involved. The activity of thrombin is the target of anticoagulant therapy. 
 During ICH, the blood-brain barrier (BBB) disruption and more precisely the alteration 
of the endothelial monolayer is an important contributor to brain hematoma expansion. The 
BBB is a physical and metabolic barrier which separates the central nervous system (CNS) from 
the blood circulation (Arai et al., 2006; Ishida et al., 2006; Yin et al., 2010). The BBB is 
composed of endothelial cells, pericytes, astrocytes, and neurons, the whole forming the 
neurovascular unit. Endothelial cells are the main components of the BBB because they restrict 
and control the passage of molecules inside and outside the brain. During ICH, the level of 
thrombin has been shown to increase and provoke disruption of endothelial cells of the BBB 
(Brailoiu et al., 2017; Hawkins et al., 2015).  
 Integrity barrier properties are ensured by the close opposition between brain 
microvascular cells. These properties are mainly provided by tight junction proteins, with the 
most important in the BBB being zonula occludens1 (ZO-1).As with other vascular barriers, 
thrombin significantly compromises BBB integrity, mediates ZO-1 decrease associated with 
damage to an adherent junction protein specific of vascular cells, i.e., vascular endothelial 
cadherin (VE-cadherin) (Festoff et al., 2016; Rabiet et al., 1996). 
 The effects of thrombin are largely mediated by the protease activated receptor (PAR) 
family composed of several isoforms, PAR-1 to 4. It has been reported that thrombin exposure 
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causes barrier disruption via activation of PAR-1(Cheng et al., 2014; Guan et al., 2004; Xi et 
al., 2003). 
 If clinical studies have shown that DOACs induced fewer ICHs than VKAs (Miller et 
al., 2012; Ogawa et al., 2011; Ruff et al., 2014), the cellular mechanisms have not yet been 
clearly established for human BBB. Hawkins et al. (2015) demonstrated that a 24-h 
pretreatment with dabigatran limited the effects of thrombin on an in vitro rodent BBB model 
(Hawkins et al., 2015). It has also been described that thrombin exposure activates PAR-1 
receptor and provokes BBB disruption. As dabigatran is a direct thrombin inhibitor, we could 
suppose that dabigatran limits PAR-1 activation and prevents BBB disruption (Chen et al., 
2015). 
In this study, our hypothesis was that DOACs may limit the effects of thrombin on brain 
endothelial cells by a mechanism probably involving PAR-1 activation. To investigate the 
effects of anticoagulant agents on thrombin-induced damage to human BBB, HBEC-5i human 
brain endothelial cells were used as a BBB model. Several DOACs, i.e., dabigatran (direct 
thrombin inhibitor), rivaroxaban and apixaban (direct Xa factor inhibitor), were compared to 
warfarin and heparin, two indirect inhibitors of thrombin.  
 Firstly, pretreatment with different anticoagulants were performed prior to the addition 
of thrombin. Trans endothelial electrical resistance (TEER) and apparent permeability (Papp) 
were investigated. Secondly, we evaluated the activation of the receptor of thrombin, PAR-1, 
and the expression of VE-cadherin and ZO-1 junction proteins.  
 
2 Results 
2.1 Impact on the tightness 
  Cells were treated with or without thrombin (1-5-10 U/mL) for 1 h. TEER, Papp with Na-
Fl and dextran-FITC were evaluated (Figure 1). The highest thrombin concentration (10U/mL) 
decreased TEER by 26% (Figure 1A) and increased Papp 5-fold to Na-Fl or dextran-
FITCcompared to control (Figure 1B-C). Our results clearly demonstrated that thrombin 
produced an alteration of the endothelial cell monolayer, the TEER and Papp values were modified 
in a concentration-dependent manner. Pretreatment effects with anticoagulant alone on 
endothelial cells of the BBB showed no effects on TEER and permeability values (Figure 1CD). 
  We then evaluated the pretreatment of anticoagulant during 24h with the highest 
thrombin concentration of 10U/mL on the endothelial monolayer (Figure 2). Depending on the 
anticoagulant used, we observed three responses of the endothelial cells after thrombin exposure.  
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  Dabigatran pretreatment allowed to maintain the BBB monolayer exposed to thrombin: 
TEER= 40.3±1.7 Ω.cm² (Figure 2A) and Papp= 7.4±0.8 x10-6 cm.s-1for Na-Fl and 4.7±0.2x10-6 
cm.s-1 for dextran-FITC (Figure 2BC). 
  Treatment with other DOACs limited the alteration of endothelial cells induced by the 
thrombin. With apixaban and rivaroxaban, we obtained TEER values of 36.2±0.7 Ω.cm² and 
37.2±0.7 Ω.cm² respectively (Figure 2A), Papp value for Na-Fl of 16.9±1.17x10-6 cm.s-1and 
20.5±0.31x10-6 cm.s-1for Na-Fl respectively (Figure 2B). We obtained Papp value of  
12.4±0.8x10-6 cm.s-1and 11.8±0.2x10-6 cm.s-1for dextran-FITC respectively (Figure 2C). 
  On the contrary, thrombin under treatment with warfarin and heparin provoked an 
alteration of endothelial cells, as represented by a low TEER (32.3±0.9 and 32.5±1.2 Ω.cm² 
respectively) (Figure 2A) and an increase in Papp (27.9±0.70x10
-6and 28.8±2.82x10-6 cm.s-1 for 
Na-Fl (Figure 2B) and 15.9±0.6x10-6 and 16.9±0.4x10-6 cm.s-1 for dextran-FITC respectively 
(Figure 2C). 
  Our hypothesis was that the breakdown of the BBB is mediated by the modulation of 
the activation of the receptor PAR-1 by thrombin.  
 
2.2Thrombin/PAR-1 pathway 
  First, we used an activator (SFLLRNPNDKYEPF) and an inhibitor (vorapaxar) of  
PAR-1 to observe the effects on TEER and Papp. 
  Vorapaxar alone had no impact on TEER and permeability (Figure 3). Preincubation of 
vorapaxar blocked the effects of thrombin on the endothelial cells. Effectively, in this condition, 
we found the same result as the control for TEER (Figure 3A), Papp for Na-Fl (Figure 3B) and 
Dextran-FITC (Figure 3C). As expected, the use of the activator of PAR-1 induced an alteration 
of the endothelial monolayer, in the same manner as for the thrombin 10IU/mL exposure (Figure 
3ABC). 
  Then we evaluated the release of the soluble fraction of PAR-1, since to be activated 
PAR-1 must be cleaved (Figure 4). The soluble fraction of PAR-1 increased after thrombin 
exposure in a dose-dependent manner (Figure 4A). The lowest concentration of thrombin allowed 
a cleavage of PAR-1 to 196±21pg soluble fraction of PAR-1/µg protein; and this value was 
increased approximately 2.5 times with the highest concentration of thrombin to obtain a high 
cleavage value of 476±6.4 pg soluble fraction of PAR-1/µg protein. 
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  Anticoagulants alone did not cleave PAR-1, as observed for the control condition 
(Figure 4B). Depending on the anticoagulant used, we observed three responses of PAR-1 
cleavage after thrombin exposure (Figure 4C). Under dabigatran, we obtained a low cleavage: 
51.6±7.8 pg soluble fraction of PAR-1/µg protein. Under rivaroxaban and apixaban, we observed 
a limited cleavage (half of thrombin alone values). Under heparin, the cleavage fraction was as 
important as that observed with thrombin exposure alone. Pretreatment with DOACs clearly 
limited the impact of thrombin on PAR-1 cleavage in our model. 
 
2.3 Effect of thrombin under anticoagulant on brain endothelial cell junctions 
  We verified that decrease in BBB tightness was associated with an alteration of cell 
junctions, the most represented being ZO-1 and VE-cadherin. Thrombin exposure (10 U/mL) 
provoked a 60% decrease in ZO-1 and a 40% decrease in VE-cadherin expressions with whole 
cell ELISA assay. 
The DOACs rivaroxaban and dabigatran prevented the decrease of both ZO-1 and VE-
cadherin expressions with whole cell ELISA assay (Figure 5AB). For the other anticoagulants, 
warfarin, heparin and apixaban, we observed a 60% decrease in ZO-1 (Figure 5A) and a 40% 
decrease in VE-cadherin expression (Figure 5B), similar to that observed in the thrombin 
condition. Immunofluorescence ZO-1 assays confirmed whole cell assays, the BBB showed more 
important disruptionlinearity at cell-cell junction zones (white arrows, Figure 5C) under warfarin, 
compared to DOACs. Immunofluorescence assays allowed to observe disrupted ZO-1 and VE-
cadherin linearity at cell-cell junctions (Figure 5CD). Immunofluorescent staining showed a 
decreased expression in VE-cadherin with thrombin. It seemed that there was more important 
disruption linearity at cell-cell junction zones (white arrows, Figure 5D) under warfarin, 
compared to DOACs. 
 
3 Discussion 
  Iatrogenic effects of anticoagulants are associated with BBB breakdown. Thrombin is a 
key factor in this rupture of the BBB (Krenzlin et al., 2016). In the literature, it was described 
that DOACs cause less intracranial bleeding compared to other classes of anticoagulants 
(Connolly et al., 2009; Miller et al., 2012; Ruff et al., 2014). The involvement of the BBB in the 
limited number of hemorrhages under DOACs was observed in vivo in rodent models with a 
lower blue Evans diffusion (Ploen et al., 2014). Few studies on the biological mechanisms are 
available to date. It seems that the activation of PAR-1 and other PARs such as PAR-3 and PAR-
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4 are implicated in the alteration or the maintaining of the barrier integrity (Festoff et al., 2016; 
Luo et al., 2007; Rohatgi et al., 2004). Our objective was to study the effects of thrombin/PAR-
1 on the endothelial cells of the BBB model under different anticoagulants and to evaluate the 
activation of PAR-1. 
  The concentration of thrombin was based on the literature; we wanted a short but 
sufficient time to induce effects and to observe a modulation(Alabanza and Bynoe, 2012; 
Hawkins et al., 2015). In human endothelial cells, maximal permeability is obtained after a 
minimum of 60 min of treatment with thrombin (Alabanza and Bynoe, 2012). First, we checked 
the effects of thrombin on BBB permeability with different parameters such as TEER and Papp. 
Our results were in agreement with the literature, we observed a decrease in TEER and an 
increase in permeability to small molecules in a thrombin concentration-dependent manner 
(Alabanza and Bynoe, 2012; Hawkins et al., 2015). 
  The concentration of dabigatran was based on Hawkins’ works, it is a clinically relevant 
concentration (Hawkins et al., 2015). For warfarin, apixaban and rivaroxaban, we chose the same 
concentration as dabigatran. Heparin can be used in many models as an adjuvant to reinforce 
BBB properties; we chose a concentration without any impact on BBB tightness. Pretreatment 
with anticoagulants before exposure of endothelial cells to thrombin was evaluated, and there 
was no effect on the tightness in the endothelial monolayer. 
We used different types of anticoagulant: DOACs, warfarin, an antivitamin K which 
corresponded to an older generation of oral anticoagulants, and heparin sodium an injectable 
anticoagulant. To our knowledge, no publication has compared all these anticoagulants at the 
cellular level to date. 
  In our studies, we observed different responses depending on the anticoagulant used. 
dabigatran, a direct inhibitor of thrombin, blocked the effects of thrombin on the BBB as 
described in the literature (Hawkins et al., 2015).  
The other DOACs apixaban and rivaroxaban are inhibitors of the factor Xa in the coagulation 
cascade, limiting the effects of thrombin on the BBB with maintaining of the integrity of the 
monolayer. The other anticoagulants warfarin and heparin at this concentration, did not limit the 
effects of thrombin on the BBB integrity. In the literature, an in vivo model with rodent showed 
a decrease of blue Evans permeability in rivaroxaban treated animals compared to warfarin 
treatment after a mechanic induction of a stroke(Ploen et al., 2014). This observation seems in 
agreement with ours. 
  Our hypothesis was that the cleavage is modulated by different anticoagulants, so we 
evaluated the cleavage of PAR-1. As expected, in our model, thrombin cleaved the receptor PAR-
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1 (Chen et al., 2015; Luo et al., 2007). As for the alteration of the endothelial monolayer, we 
observed different responses depending on the anticoagulant used. In the literature it has been 
demonstrated that the expression of the protein PAR-1 can be modulated in the presence of 
warfarin, this mechanism has not been observed with DOACs (Morihara et al., 2017). 
  As described in the literature, the thrombin-bound dabigatran blocks the cleavage of 
PAR-1 preventing its activation that leads to BBB breakdown(Chen et al., 2015). We obtained 
the same results with dabigatran in our model. 
  The other DOACs limited the cleavage of PAR-1 by thrombin. The other anticoagulants 
(warfarin, heparin) did not limit the cleavage of PAR-1. Our results are original and have not 
been reported in the literature on the BBB. These results are in agreement with the modulation 
of the tightness of the endothelial cells in a BBB model. 
  We have studied the ZO-1tight junction protein which plays a key role in the tightness 
of the BBB. It has been described that this junction is impacted in response to treatment with 
thrombin on endothelial cells(Alabanza and Bynoe, 2012; Brailoiu et al., 2017; Machida et al., 
2017). VE-cadherin is an adherent junction protein characteristic of vascular endothelial cells. It 
has been shown that this junction protein is the first to be altered in response to thrombin 
treatment on endothelial cells; its alteration can induce ZO-1 alteration in a second 
time(Kustermann et al., 2014; Rabiet et al., 1996).It seems that under the action of thrombin, 
mediated by PAR-1 activation, the VE-cadherin and ZO-1 junction proteins are phosphorylated 
and removed from the membrane for ZO-1, which would decrease their availability to bind to 
other junction proteins(Sabath et al., 2008; Timmerman et al., 2010). The activation of the 
receptor PAR-1 can also result in the endocytosis of junctions (Keep et al., 2018). In our model, 
thrombin induced a modification in expression of ZO-1 and VE-cadherin, and this modulation 
was limited by pretreatment with dabigatran and rivaroxaban before thrombin exposure; whereas 
the other anticoagulants did not limit this effect. The results obtained with the cell ELISA assay 
can be explained by the non possibility of the antibody to bind to the protein due to 
phosphorylation or internalization of junctions. This result is in agreement with the observation 
in immunostaining assays. 
 
4 Conclusion  
  DOACs seem to act on PAR-1 cleavageand is directly related to the permeability of the 
cell barrier. DOACs limit the rupture of the BBB mediated by the thrombin/PAR-1pathway. 
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  All these different responses between DOACs and other classes of anticoagulants 
reinforce our hypothesis of a limitation, under DOACs, especially rivaroxaban and dabigatran, 
of the BBB breakdown mediated by the thrombin/PAR-1 pathway. 
  In this study, we have only observed the effect of anticoagulants and thrombin on the 
endothelial cell. To better understand the result of clinical studies that have shown that DOACs 
induced fewer ICHs than VKAs, a more complex model with other cells of the BBB is necessary. 
 
5 Material and methods 
5.1 Chemicals and reagents 
  Bovine serum albumin (BSA), sodium fluorescein (Na-Fl), BCA assay kit QuantiPro, 
DMEM-F12 HAM (Dulbecco's Modified Eagle Medium: nutrient Mixture F-12), Hank’s 
balanced salt solution (HBSS), Dulbecco’s phosphate buffered saline without sodium and 
magnesium (DPBS), fetal bovine serum (FBS), trypsin, antibiotic and antimycotic solution, 
fluorescein isothiocyanate dextran (dextran-FITC 4kDa), HEPES buffer, 3,3′,5,5′-
tetramethylbenzidine (TMB), hydrogen peroxide solution (H2O2), Ser-Phe-Leu-Leu-Arg-Asn-
Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe (SFLLRNPNDKYEPF) peptide were purchased from 
Sigma-Aldrich (St. Quentin Fallavier, France). Rabbit anti-ZO-1 (ab59720) and rabbit anti-VE 
cadherin (ab33168) antibodies were purchased from Abcam (Cambridge, United Kingdom). 
Secondary antibodies for cell ELISA were purchased from Santa Cruz Biotechnology (Dallas, 
USA). The F2R ELISA kit for PAR-1 measurement was purchased from Aviva Systems Biology 
(San Diego, USA). Rivaroxaban, dabigatran, apixaban and vorapaxar were purchased from 
Alsachim (Illkirch, France). Heparin sodium was purchased from Panpharma (Luitré, France). 
Coumadin (warfarin) was purchased from Brystol-Myers Squibb (NewYork, USA). Bovine 
thrombin was purchased from Siemens Healthcare (Erlangen, Germany). Normal goat 
supplement (NGS) was purchased from Millipore (Burlington, USA). Secondary antibody 
(Alexa Fluor 555 goat anti-rabbit (A-21429)) and 4', 6-diamidino-2-phenylindole (DAPI) for 
microscopy were purchased from Thermo Fischer Scientific (Massachusetts, USA). Vectashield 
Mounting Medium (H-1000) was purchased fromVector Laboratories (Burlingame, USA). 
Cell culture inserts for 24-well plates (high density pore, 0.4 μm pore diameter size, 
translucent or translucidepolyterephtalate ethylene (PET) membrane) were purchased from 
Becton Dickinson (Franklin Lakes, USA). The EVOMvoltohmmeter system was purchased from 
World Precision Instruments (Hertfondsire, UK). 25 cm2 culture flasks and companion plates 
were purchased from Dominique Dutscher (Strasbourg, France). 
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5.2 HBEC-5i BBB culture 
 The model was composed of HBEC-5i endothelial cells (from ATCC-Manassas, VA, 
USA) cultivated with conditioned medium from human astrocytes(HA from ScienCell Research 
Laboratories, Carlsbad, CA, USA) as previously described (Puech et al., 2018b).Cells were 
cultured in DMEM-F12 HAM, supplemented with 10% FBS and 1% antibiotic antimycotic 
solution. Cells were maintained in a humidified incubator at 5% CO2 and 37°C.  
 
5.3 Treatments  
  Cells were incubated with or without dabigatran, rivaroxaban, apixaban, warfarin (at 0.5 
µM physiological dose based on Hawkins (Hawkins et al., 2015)), and heparin (at 10 IU/mL) for 
24 h. Cells were then treated with or without thrombin at 1, 5, or 10 IU/mL for1 h to mimic a 
haemorrhagic event(Alabanza and Bynoe, 2012; Hawkins et al., 2015).We used vorapaxar and 
SFLLRNPNDKYEPF as inhibitor and activator of the thrombin/PAR-1 pathways respectively. 
 
5.4 Barrier properties 
 The apparent permeability (Papp) was assessed using two hydrophilic fluorescent 
molecules: Na-Fl (MW = 376 Da) or dextran-FITC (MW= 4 kDa). HBSS transporter buffer 
supplemented with 10 mM HEPES containing 10µg/mL of Na-Fl or dextran-FITC was loaded 
onto the apical side of the insert and incubated at 37°C for 1 h. Fluorescence was measured with 
a fluorescence spectrophotometer (FluoroskanAscentTM, Thermo Fischer scientific, France) with 
485 nm excitation and 530 nm emission wavelengths. The permeability for all molecules was 
computed using the following formula:  
𝑃𝑎𝑝𝑝 =
𝑉𝑟
𝐶0
×
1
𝑆
×
𝐶1
𝑡
 (Formula 1) 
 Where Papp is the apparent permeability, Vr is the volume of medium in the receiver 
chamber, C0 is the concentration of fluorescent compound in the donor chamber at T0, S is the 
surface area of the monolayer, C1 is the concentration of fluorescent molecule in the receiver 
chamber after 1 h of incubation and t is the incubation time. The results are express in cm.s-1 
(Puech et al., 2018a).  
 Trans endothelial electrical resistance (TEER) was recorded using an EVOM® 
resistance meter with STX-2 electrode to characterize the formation of a tight endothelial cell 
monolayer. The measurement of a blank filter, i.e. without cells, was subtracted from those of a 
filter with cells. Then the resulting value was multipliate by the membrane area to obtain the 
TEER measurement in Ω.cm².  
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5.5 Thrombin, PAR-1 pathway 
  PAR-1 is activated by proteolytic cleavage of its extracellular N-terminus domain, 
resulting in the formation of a novel N-terminus (with sequence: SFLLRNPN) that serves as a 
tethered ligand folding back into the ligand-binding pocket of the receptor PAR-1. 
PAR-1 activation is evaluated with the cleavage of PAR-1 based on standard sandwich ELISAs. 
Measurements were realized according to the manufacturer’s recommendation. The result was 
normalized by micro BCA total protein assay according to the manufacturer’s instructions. 
 
5.6 Protein expression 
5.6.1 Whole cell ELISA 
 Cells were seeded onto a 96-well plate at a density of 10,000 cells/well. At confluence, 
cells were treated with anticoagulants for 24 h and/or thrombin at 10 IU/mL for 1 h.  
Then cells were fixed with 4% paraformaldehyde and permeabilized with methanol with 3% 
H2O2. ZO-1 and VE-cadherin expressions were evaluated in our model with primary polyclonal 
antibodies diluted 1/200 and incubated at room temperature. Secondary IgG antibody diluted at 
1/500 was incubated at room temperature. Then, streptavidin was added for20 min at room 
temperature. TMB substrate was added in each well. At the end the reaction was stopped by 
addition of hydrochloric acid 1N and was measured with a spectrophotometer (MultiskanTM RC, 
Thermo Fischer Scientific, France) at 450 nm. Our results were normalized with the total protein 
content as assessed by Coomassie blue total protein assay, according to the manufacturer’s 
instructions. 
 
5.6.2 Immunofluorescence studies 
 BBB on inserts were fixed in glacial methanol for 6 min and rehydrated. Following a blocking 
step, the inserts were cut and placed in 24-well plates. Primary antibodies were diluted at 1/200 
and incubated for 1 h. Secondary antibodies were diluted 1/500 and incubated with an insert 
membrane for 45 min. Nuclei were finally counterstained with DAPI in PBS at room temperature 
for 30 min. The staining of all biomarkers had been imaged using an epifluorescence inverted 
microscope IX81 (Olympus, Tokyo, Japan) equipped with CellSens imaging software (Olympus, 
Munster, Germany). FIJI software was used to treat the image. 
 
5.7 Statistical Analysis 
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Graphpad software was used for data analysis and graphic outputs. Data were expressed as the 
mean ± standard deviation. Statistical analyses were performed using Graphpad software 
(Graphpad Software Incorporation, San Diego, USA). A Mann-Whiney test was used. Treated 
samples were compared to untreated control. The differences were considered statistically 
significant when p-value<0.05. 
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Figures legends 
 
Figure 1: Effect of thrombin and anticoagulants on the endothelial cells of the blood brain 
barrier (BBB) model. A: Mean Trans endothelial electrical resistance (TEER) values for BBB 
model with three concentrations of thrombin after an incubation of 1h. Mean ± SD n= 3 N=5. 
B: Apparent permeability (Papp) values for sodium fluorescein (Na-Fl) (full circle) and dextran-
FiTC (empty circle) in the same configuration. C: Mean TEER values for BBB model with 
several anticoagulants after an incubation of 24 h n=3. D: Papp values for Na-Fl with the same 
anticoagulant. * p-value<0.05; ** p-value<0.01; ***p-value<0.005 compared to untreated 
control as determined by a Mann-Whitney test. 
 
Figure 2: Effect of anticoagulant pretreatment on the endothelial cells of blood brain barrier 
(BBB) damage caused by thrombin. A: Mean trans endothelial electrical resistance (TEER)  
values for the effect of pretreatment with anticoagulant for24 h before an exposure of thrombin 
at 10 IU/mL for 1 h Mean ± SD n=3 N=2. Apparent permeability (Papp) values for sodium 
fluorescein (Na-Fl) (B) and dextran-FITC (C) on the same configuration. Mean ± SD n=3. * 
p-value<0.05; ** p-value < 0.01; ***p-value<0.001 compared to untreated control as 
determined by a Mann-Whitney test. 
 
Figure 3:  Effect of activator and inhibitor of the protease activated receptor-1 (PAR-1) 
pathways on the blood brain barrier (BBB). A: Mean Trans endothelial electrical resistance 
(TEER) values for vorapaxar (inhibitor of PAR-1) for24 h alone or with thrombin for1h and 
SFLLRNDKYEPF (activator of PAR-1) for1 h. Mean ± SD n=3, N=2. Apparent permeability 
(Papp) values for sodium fluorescein (Na-Fl) (B) and dextran-FITC (C) on the same 
configuration. Mean ± SD n=3. * p-value<0.05; ** p-value < 0.01; ***p-value<0.001 
compared to untreated control as determined by a Mann-Whitney test. 
 
Figure 4: Effect of thrombin with or without anticoagulant on the cleavage of the protease 
activated receptor-1 (PAR-1). A: Evaluation of the expression of soluble fraction of PAR-1 in 
the supernatant of HBEC-5i after exposure to different concentrations of thrombin for1h. B: 
Evaluation of the expression of the soluble fraction of PAR-1 in the supernatant of HBEC-5i 
after exposure to anticoagulants for24 h. C: Evaluation of the expression of the soluble fraction 
of PAR-1 in the supernatant of HBEC-5i after a pretreatment with anticoagulant before 
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thrombin exposure. Mean ± SD n= 4. * p-value < 0.05; **p-value<0.01 compared to untreated 
control as determined by a Mann-Whitney test. 
 
Figure 5: Evaluation of the effect of thrombin under anticoagulant exposure on ZO-1 and VE-
cadherin junction proteins. A: Cell ELISA for ZO-1 expression with thrombin alone or after a 
pretreatment with anticoagulant. Mean ± SD n=4 N=2. B: Cell ELISA for VE-cadherin 
expression in the same configuration. * p-value < 0.05; ** p-value < 0.01; ***p-value<0.005 
compared to untreated control as determined by a Mann-Whitney test. 
Immunostaining of ZO-1( C) or VE-cadherin (D) in control condition (1) and after 10IU/mL 
thrombin incubation (2), or pretreatment before thrombin: dabigatran (3), rivaroxaban (4), 
apixaban (5), warfarin (6). Scale bar=50µm.  
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